Download Coory M, Baade P, Aitken J, Smithers BM, McLeod GR, Ring I

CURRICULUM VITAE: Bernard Mark SMITHERS
ACADEMIC ADDRESS:
Department of Surgery, University of Queensland, Princess
Alexandra Hospital, Ipswich Rd., Brisbane, Australia 4102
PRIVATE PRACTICE:
GIAST Clinic, Suites 30,31 Mater Medical Centre, 293 Vulture St.,
South Brisbane, Australia 4101
E MAIL:
[email protected]
PLACE
OF BIRTH:
Brisbane, Queensland.
EDUCATION:
TERTIARY:
University of Queensland 1972-1977 M.B.B.S.
POSTGRADUATE: Fellow Royal Australasian College of Surgeons, Feb 1985
Fellow Royal College of Surgeons of England, Jan 1986
QUALIFICATIONS:
M.B.B.S.(Qld), F.R.A.C.S., F.R.C.S.(Eng).
PRESENT APPOINTMENTS:
ACADEMIC: Associate Professor of Surgery, University of Queensland (Part Time)
Level D, Academic (Point 0404)
Honorary Associate, NH&MRC Trials Centre, Faculty of Medicine,
University of Sydney
CLINICAL:
Senior Visiting Medical Officer - Trauma/General Surgeon,
Director, Upper GI and Soft Tissue Unit, Princess Alexandra Hospital.
PREVIOUS APPOINTMENTS:
Consultant Surgeon Appointments.
• Locum Surgeon, Flying Surgeon Service, Longreach, Australia, Jan 1987.
• Locum Vascular Surgeon, Princess Alexandra Hospital, Jan-Feb 1988.
• Visiting Consultant Surgeon, Logan Hospital, June 1990-91.
• Clinical Lecturer, University of Queensland, Department of Surgery, Princess Alexandra
Hospital, Brisbane. Sept 1987 - June 1988.
• Senior Lecturer in Surgery, University of Queensland, Department of Surgery,
Trauma/General Surgeon, Princess Alexandra Hospital, Brisbane. June 1988 - April
1995.
• Associate Professor in Surgery, University of Queensland, Department of Surgery,
Princess Alexandra Hospital, Brisbane. May 1995 • Visiting Surgeon, Upper GI and Soft Tissue, Unit Princess Alexandra Hospital, Brisbane.
May 1995 - July 1996
• Senior Visiting Surgeon, Director, Upper GI and Soft Tissue Unit, Princess Alexandra
Hospital, Brisbane. July 1996 – present time
LICENSURE: Medical Board of Queensland.
General Medical Council of England.
SPECIALTY CERTIFICATION: General Surgery
PROCEDURAL CERTIFICATION: Colonoscopy, Gastroscopy
PROFESSIONAL MEMBERSHIPS:
1978
Medical Defence Society of Queensland 1978-1997
1980
Australian Sports Medicine Federation 1980-2006)
1982
Visa Qualifying Examination of Educational Commission for Foreign
Medical Graduates (E.C.F.M.G.)
1985
Royal Australasian College of Surgeons (Current)
1986
Royal College of Surgeons of England (Current)
1986
World Association of Hepato Pancreatico-Biliary Surgeons
1988
Gastroenterological Society of Queensland (Current)
1991
Clinical Oncological Society of Australia (Current)
1992
Gastroenterological Society of Australia (1992 – 2008)
1992
Surgical Research Society of Australasia (Current)
1994
Eastern Co-operative Oncology Group (E.C.O.G.) - Investigator (Current)
1997
United Medical Protection Society (1997 - 2007)
1998
International Association of Hepato-pancreaticobiliary Surgeons(Current)
1999
International Society of Diseases of the Esophagus(Current)
2000
Society of Surgical Oncology (USA)- (Current)
2007
Australia and New Zealand Gastro-Oesophageal Surgeons Association
(Current)
2007
Avant Medical Insurance (Current)
AWARDS:
1992:
2003:
2007:
2008:
Queensland Cancer Fund - E.S.A. International Scholarship
Study and Travel Programme:
MD Anderson Cancer Centre - Houston, Texas,
Department of Surgery, University of Kentucky, Louisville, Kentucky
Memorial Sloan Kettering Cancer Institute, New York.
Prince of Wales Hospital, Chinese University, Hong Kong.
Philip Goatcher Surgeon in Residence – Royal Perth Hospital.
July, Perth
Nimmo Visitor – Royal Adelaide Hospital
October 29 – November 1, Adelaide, Australia.
Distinguised Invited Visitor - Combined Royal Australasian College
of Surgeons and College of Surgeons of Hong Kong Annual Scientific
Congress. May 13 – 18, Hong Kong
CLINICAL INTERESTS:
UPPER G.I. SURGERY - I am one of four Surgeons and the Chairman/ Director of the Upper
G.I./Soft Tissue Unit at Princess Alexandra Hospital.
My interests and research include:
(i)Malignant diseases of the oesophagus and stomach. In 1994 we established a multidisciplinary Upper GI Oncology Clinic, involving surgery, medical oncology and radiation
oncology. We presently run a weekly multidisciplinary meeting to discuss all new and problem
cases of cancer of Gastric and Oesophageal Malignancy. All oesophageal and gastric
malignancies are documented onto a prospective database. We see over 100 new patients with
malignant dysphagia each year and operate on 45%.
(ii) Benign conditions notably Gastro-oesophageal Reflux. In collaboration with my colleagues
Professor David Gotley and Les Nathanson we are documenting all patients who have had
surgery.
(iii) We are a tertiary referral centre for complicated upper GI problems including patients with
Achalasia and those who have had previous surgery with functional problems.
MELANOMA - I am the Senior Surgeon in the Melanoma Clinic at Princess Alexandra
Hospital. This is a multi-disciplinary clinic with medical oncology and radiotherapy, and is the
base for the initiation of a number of clinically based research projects and trials. I am Chairman
of The Queensland Melanoma Project which is the research arm of the Melanoma Clinic. This
group runs and co-ordinates the clinically based trials for patients managed through the
Melanoma Clinic.
ENDOSCOPY - DIAGNOSTIC - I am accredited in colonoscopy and gastroscopy with the
combined committee of the G.E. Society of Australia and the Royal Australasian College of
Surgeons.
ENDOSCOPIC SURGERY - I am experienced in advanced Laparoscopic Surgery including
cholecystectomy, Nissen fundoplication, oesophageal resection, adrenalectomy and splenectomy.
At the time of the introduction of laparoscopic surgery, I had been on the teaching faculty for
practical courses, as well as attending many workshops.
I have coordinated a prospective randomised trial of open versus laparoscopic appendicectomy.
TRAUMA - The Princess Alexandra Hospital is a major metropolitan hospital dealing with
primary, secondary and tertiary referrals of patients with major trauma. I am interested in the
assessment, care and documentation of these patients. In the past I had the responsibility to
organize the trauma roster and service with my earlier appointment to the hospital including the
title of Trauma surgeon.
I have been a Director and Instructor of the Early Management of Severe Trauma Course which
is run by the Australasian College of Surgeons. I have taught on a number of courses in
Australasia and more recently have directed a number of participant and instructor courses. From
January 1995 to February 2000 I was on the national EMST Committee.
RESEARCH
OESPHAGUS – Active
NH&MRC:
APP 1011782 – Docetaxel with or without radiation therapy for resectable oesophageal
adenocarcinoma based on early PET response to induction chemotherapy. (DOCTOR trial)
CIA Andrew Barbour; CIB Bernard Smithers, CIC Bryan Burmeister, CID Euan Walpole,
CIE John Zalcberg, CIF Nigel Spry, CIG Garett Smith
2011 – 13: $791,991.44
 “Prospective assessment of Quality of Life after Intervention for oesophageal cancer”.
Chief Investigators: Assoc. Prof. M Smithers, Professor D Gotley
Support: Mater Private Hospital
 Prospective documentation of Oesophageal and Gastric cancers managed within Princess
Alexandra Hospital and the Mater Medical Centre.
OESPHAGUS – COMPLETED
NIH
Molecular epidemiology of Barrett’s oesophagus and cancer.
Chief Investigator: David Whiteman
Associate Investigators: G. Jameison, A Green, D Purdie, D Gotley, BM Smithers, D. Watson
Support: National Institute of Health, USA - $US 1,250,000 2003 – 08.
NHMRC
Towards Prognostic Markers for Oesophageal Cancer
Chief Investigator: David Whiteman
Associate Investigators: Assoc Prof BM Smithers, Prof DC Gotley, Prof A Green
Support: NH&MRC: 2006-8
Randomized trial of Surgery alone compared with chemoradiation prior to surgery for operative oesophageal
carcinoma. This was a National multicentred trial co-ordinated by a management committee under the auspices of
the Australasian Gastro Intestinal Trials Group and the Trans-Tasman Radiation Oncology Group.
Chief Investigator: Assoc. Prof. B Burmeister
Principle Investigators: Assoc. Prof. M Smithers, Prof. J Denham, Dr S Ackland
Support: NHMRC 1996-1998 - $73,000 per annum
Epidemiology of Oesophageal Cancer.
Chief Investigator: David Whiteman
Associate Investigators: Prof Adele Green, Assoc Prof M Smithers, Prof. David Gotley
Support: Queensland Cancer Fund - $60,000 per annum 2001- 2002
NH&MRC programme grant to Queensland Institute of Medical Research
Randomised Phase II trial of preoperative chemotherapy compared with preoperative chemoradiation for
operable carcinoma of the oesophagus
Investigators: Assoc Professor B. Burmeister, Assoc Professor M. Smithers, Prof D. Gotley, J. Harvey, E.
Walpole, D. Thomson.
Support: Internal
GASTRIC CANCER - Active
Cancer Australia
Randomised phase III study of preop-chemoradiotherapy vs preop-chemotherapy for
resectable gastric cancer.
Support: Cancer Australia 570996 (app ID) $596625, 2009-2011
Chief Investigator: Trevor Leong,
Associate Investigators: Val Gebski, Mark Smithers, David Watson, Nigel Spry, John
Zalcberg, Michael Michael, Alex Boussioutas
GIST – Completed
Intermediate and high risk localized, completely resected, gastro-intestinal stromal tumours (GIST)
expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no
further therapy after complete surgery. Intergroup study (EORTC 62024). – 5%
Australian sponsor; Australasian Gastrointestinal Trials Group (AGITG)
Trial Management Committee: Dusan Kotachek, BM Smithers, B. Mann, G Van Hazel,
Garret Smith, D Porter, D Watson, S Pieterse, J Simes, J Zalcberg, D Miller, M Hall
2005 - $90002, 2006 - $87002, 2007 - $76168
ENDOSCOPIC SURGERY - Active
• “Pre and post-operative assessment for laparoscopic fundoplication”.
This study utilizes oesophageal physiology studies and quality of life instruments to
objectively assess the results of all patients who have anti-reflux surgery, both in the short
and long term.
• Prospective documentation of advanced laparoscopic surgery – cardiomyotomy,
splenectomy, adrenalectomy
MELANOMA - Active
NH&MRC:
APP 1004999: Effects of nevogenesis susceptibility genes and phenotype correlation with
dermoscopic characteristics of nevi.
CIA Peter Soyer, CIB Richard Sturm, CIC David Duffy, CID Bernard Smithers.
2011 -13, $535,206
Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter
Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection
versus Sentinel Lymphadenectomy Alone in CutaneousMelanoma Patients with Molecular
or Histopathological Evidence of Metastases in the Sentinel Node.
Multicentre trial co-ordinated by John Wayne Cancer centre.
PI Donald Morton
Local Investigators: BM Smithers, Gerard Bayley, Andrew Barbour
A phase 2 study of intralesional PV-10 in the treatment of metastatic melanoma.
Sponsor – Provectus Pharmaceuticals, Delpharm Consultants
Chief Investigator (Qld) – BM Smithers
Co-investigators – A Barbour, G. Bayley
A phase I study of Genvax for Stage IV metastatic Melanoma.
Sponsor –
Chief Investigator – BM Smithers
Co-investigators – A Barbour, G Bayley, D. Thomson
DERMA Study - A phase III study of MAGE for patients with stage III metastatic
melanoma.
Sponsor – GlaxoSmithKline Biologicals
Chief Investigator (Qld) – BM Smithers
Co –investigators – A Barbour, G Bayley, D Thomson
MELANOMA RESEARCH - COMPLETED
NH&MRC
Treatment of recurrent malignant melanoma by limb infusion of cytotoxic drugs and other techniques.
Chief Investigator: Prof M Roberts
Principle Investigators: A/Prof BM Smithers, A/Prof J Thompson and A/Prof C Anderson
Support NHMRC #981314: 1998 – 2000 $273,453
Preclinical development of a melanoma – selective drug:
Chief Investigator: Dr P Parsons
Principle Investigator: Assoc. Prof M Smithers
Support: NHMRC 1998 – 2000 - $60,000 per annum
The role of TAPP and MHC Class ! expression in the response to melanoma immunotherapy using dendritic
cells.
Chief Investigator: Assoc Prof R Thomas
Principle Investigators: Dr. Jabbar, Assoc Prof BM Smithers, E Walpole
Support NH&MRC # 102515: 2000 – 2002 $104,000 per annum
Clinical trial of Autologous Melanoma Vaccine in Patients with Stage IV melanoma
Chief Investigator: Dr R Thomas
Associate Investigators: Assoc. Prof M Smithers, Dr E Walpole, Clinical Prof R McLeod
Support: Queensland Cancer Fund – 1999 – 2000 $40,000 per annum
NH&MRC 2000 – 2002 $103,000 per annum
Phase III trial of an immunotherapy for stage III (AJCC) melanoma based on cultured autologous dendritic
cells presenting autologous tumour cell analysis.
Investigators: Prof Michael O’Rourke, A/Prof BM Smithers, Prof K. Ellem, C Schmidt, B O’Loughlin, D Lincoln
Support: 2003-05 NH&MRC project grant to Queensland Institute of Medical Research
2006 – MS Principle Investigator - Queensland Cancer Fund (Grant Q57) – 2 years 71,700 per annum.
A trial of surgery versus surgery plus adjuvant radiotherapy in patients with resected nodal metastatic
melanoma.
Chief Investigator: M. Henderson, Peter MacCallum Cancer Centre, Melbourne
Associate Investigators: W. McCarthy, J. Thompson, B. Burmeister, BM Smithers
Support: NH&MRC - $305000, 2003 – 06
"Physiological Pharmacokinetics in the Isolated Limb".
Chief Investigators: M. Smithers / Prof. M. Roberts
Associate Investigator: Prof. W. Egerton
Support: Queensland Cancer Fund 1993 - $60,000
University of Queensland - Cancer Research Fund 1994 - $31,400
Queensland Cancer Fund 1995-97 - $45,000 per annum
Princess Alexandra Hospital Foundation 1997 - $10,000
Publications: 7 Posters: 4
Pharmacokinetics and pharmacodynamics of isolated limb perfusion and isolated limb infusion.
Chief Investigator:
Prof. M Roberts
Principle Investigators: Assoc. Prof J Thompson, Assoc. Prof M Smithers, Dr C Anderson
Support: Princess Alexandra Hospital Foundation 1998 - $10,000
Development of Autologous Melanoma Vaccine for patients with stage IV metatastic melanoma.
Chief Investigator: Dr R Thomas
Associate Investigators: Assoc. Prof M Smithers, Dr E Walpole, Clinical Prof R McLeod
Support: University of Queensland – Cancer Research Fund – 1998
Queensland Cancer Fund – 1999 – 2000 $40,000 per annum
Phase III multicentred trial of wide excision alone versus wide excision and selective lymphadenopathy for
malignant melanoma
Investigators: Assoc. Prof. M Smithers, Clinical Prof R McLeod
This trial is co-ordinated by the John Wayne Institute – California, USA
Commenced 1998. Accrual closed, follow up continues.
Support: John Wayne Cancer Institute - $73,400 (to 2004)
A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy with
BCG plus a Polyvalent Melanoma Vaccine, CancerVaxTM Vaccine, versus BCG plus a Placebo as a PostSurgical Treatment for Stage III Melanoma. (Multicentred trial)
Principle Researcher: BM Smithers
Associate Researchers: S. Jones, B. Burmeister, G. Bayley
Sponsor: CancerVax Corporation, Santa Monica, USA
A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy with
BCG plus a Polyvalent Melanoma Vaccine, CancerVaxTM Vaccine, versus BCG plus a Placebo as a PostSurgical Treatment for Stage IV Melanoma. (Multicentred trial)
Principle Researcher: BM Smithers
Associate Researchers: E Walpole, G. Bayley
Sponsor: CancerVax Corporation, Santa Monica, USA
A Phase II Trial of Immunotherapy with BCG plus a Polyvalent Melanoma Vaccine, CancerVaxTM Vaccine, in
patients with in-transit metastatic melanoma. (Multicentred trial)
Institutional Principle Researcher: BM Smithers
Associate Researchers: E Walpole, G. Bayley, S. Jones, A. Barbour
Sponsor: CancerVax Corporation, Santa Monica, USA
Phase I open label cohort study of two doses of Cavatak (coxsackievirus A21) given intratumorally in stage
IV melanoma.
Sponsor – Virolytics 2006-09
Chief Investigator (Qld) – BM Smithers
OTHER:
"Studies of the Abrogation of Islet Destruction by Immunointervention". 1987-1990.
Chief Investigator: Dr. M. Green
Associate Investigator: M. Smithers
This project was supported by the Department of Surgery at Princess Alexandra Hospital.
Publications: 1
Posters: 7
OTHER CLINICAL – completed :
“Randomised study of laparoscopic appendectomy versus open appendectomy”. (Published)
“Study of General Surgical aspects in Severe Pelvic Trauma”, managed at Princess Alexandra Hospital.
“Peri-operative assessment audit of the first 100 patients having laparoscopic cholecystectomy”, at Princess
Alexandra Hospital.
TEACHING:
Undergraduate – Medical 1987 - 99
Year 5 – Coordinator & Examiner of Medicine V Studies 1993 – 9
Surgical pathology tutorials 1 hour/week
Small group tutorials 1 hours/week
Large group seminars 2 hours/week
Lectures – nine per year.
Year 6 - Tutorials
Undergraduate –
Physiotherapy Year 2 - Two Lectures
Graduate Medical Course: 2000 - present
Year3 – Clinical Bedside Coaching and Tutorials
Year 2: Lecture – “Malignant melanoma”
Postgraduate
 Surgical Trainee teaching sessions and clinical discussions.
 Tutorials on anatomy and surgical pathology.
 Lecture to Family Medicine Programme on abdominal pain and melanoma. 1990 - 99
 AMC Candidates – Lecture on Trauma 2000 -2003
Post-Graduate Student Supervision
1992: A. Grabs - Master Medical Science
ADMINISTRATION
PRESENT
Royal Australasian College of Surgeons
 Member, Queensland State Committee, RACS, 2006 – present
 Executive, Section of Academic Surgery
Australian and New Zealand Gastro-Oesophageal Surgeons Association (ANZGOSA).
 Vice President, 2006 – 2010 (President elect)
 President, 2010 Queensland Institute of Medical Research
 Member, Medical Advisory subcommittee 2001 – Present
Princess Alexandra Hospital
 Director, Upper GI / Soft tissue Unit 1996 – Present
 Princess Alexandra Foundation, scientific advisory committee, 2006
Australasian Gastrointestinal Trials Group
 Member, Scientific advisory committee 1995 – present
Queensland Health
 Member, State Surgery Advisory Committee, 2008 – present
 Chair, Oesophago-gastric cancer collaborative, 2009 - present
Mater Private Hospital
 Member, Operating Theatre advisory committee 2002 – 2007
 Chair, Operating Theatre advisory committee 2008 - present
Melanoma Patients Australia
 Medical Director
Melanoma Advisory Foundation
 Trustee
ADMINISTRATIVE - PAST
University of Queensland
• Coordinator and Chief Examiner V year surgery 1993 – 1999
Royal Australiasian College of Surgeons
• Organising Committee. R.A.C.S. Qld Branch, Annual Scientific Meeting, 1988.
• Chairman, Organising Committee - Symposium on the Acute Abdomen, Sheraton Hotel, November 1990.
R.A.C.S. C.M.E. Activity.
• RACS Supervisor of Surgical training, Princess Alexandra Hospital 1992 - 1996.
• Executive, Organising Committee and Member of the Scientific Committee, Annual Scientific Congress
for RACS 1997.
• National Committee, Early Management Severe Trauma course 1995-2000
• Member, Regional Subcommittee of the Board in General Surgery 1992 – 1996
• Chairman, Regional Subcommittee in General Surgery 1996 – 2002
• Member, National Board of General Surgery 1996 – 2002
 Scientific Convener, RACS Annual Scientific Congress, 2003
 Convener, Section Surgical Oncology, RACS Annual Scientific Congress, 2003
 Examiner Primary OSCE 1991 – 2008
 Convener, Annual Scientific Congress, RACS, 2008
 Executive, Section of Surgical Oncology, 2001 – 2010
 Member, Court of examiners, General Surgery, 2002 – 2010
Princess Alexandra Hospital
• Establishment of Surgical Services at Logan Hospital and then subsequent provision of part-time service.
June 1990-1991.
• Representative to Post Graduate Medical Education Committee 1996
Queensland Health
 Chair, Southern Zone Surgical Network, 2006 – 2010
Holy Spirit Hospital
• Ethics Committee, medical representative 1995 – 1999
• Medical Advisory Committee 1997 – 99
Clinical Oncological Society Of Australia
• Convenor Section of GI oncology, Annual Scientific Meeting, 1996
•
Chairman, Surgical Oncology Group, 1997 – 2000
•
Member of National Council, 1997 – 2000
• Convenor, Section Surgical Oncology, Annual Scientific Meeting, 2000
 Convenor, Sections Surgical Oncology and Melanoma, Annual Scientific Meeting, 2005
Gastroenterological Society of Queensland
• Executive Committee, 1990 – 1999
Queensland Institute of Medical Research
•
Member of Governing Council 1997 – 2001 (Ministerial Appointment)
Queensland Clinical Oncology Group
• Member of the interim executive committee, 2000 - 2003
• Member of the Commissioning team, 2000 – 2003
Peplin Biotech Pty/Ltd
• Medical Advisory Committee 2000 – 2006
Queensland Cancer Registry
• Member, Advisory Committee, 2002 – 2008
BIBLIOGRAPHY
Hickey MT, Williams PF, Webb EG, Hoedl AF, Wurm MT, Douglas NC, Smithers BM, Green
AC, Soyer HP. Naevus surveillance pilot study: evaluation of a protocol for phenotypic naevus
characterization. Aust J Dermatol 2011; In Press
Baade PD, Green AC, Smithers BM, Aitken JF. Trends in melanoma incidence among children:
possible influence of sun protection programs. Exp Rev Anticancer Ther 2011;11:661-664.
Zingg U, Smithers BM, Gotley DC, Smith G, Aly A, Clough A, Esterman AJ, Jamieson GG,
Watson DI. Factors associated with post-operative pulmonary morbidity after oesophageal
resection for cancer. Ann Surg Oncol 2010;18:1460-68
Hirst J, Smithers BM, Gotley DC, Martin I, Thomas J, Barbour A. Actual 5-Year Survivors
following oesophagectomy and predictors of survival. Ann Surg Oncol 2011;18:1766-74
Burmeister BH, Thomas JM, Burmeister E, Walpole ET, Harvey JA, Thomson DB, Barbour AP ,
Gotley DC, Smithers BM. Is concurrent radiation therapy required in patients receiving
preoperative chemotherapy for adenocarcinoma of the oesophagus ? – a randomised phase II trial.
Eur J Cancer 2011; 47:354-360
Barbour AP, Jones M, Brown I, Gotley DC, Martin I, Thomas J, Clouston A, Smithers BM.
Risk stratification for early esophageal adenocarcinoma: Analysis of lymphatic spread and
prognostic factors. Ann Surg Oncol 2010;17:2494-2502
Baade PD, Hernandez EH, Freedman DM, Smithers BM, Fritschi L. No role for melanoma
treatment in the association between melanoma and amyotropic lateral sclerosis or Parkinson’s
disease. Neuroepidemiology 2010;35:303-304
Smithers BM, Fahey PP, Corish T, Gotley DC, Falk GI, Smith GS, Kiroff GK, Clouston AD,
Whiteman DC, for the Austalian Cancer Study. Symptoms, investigations and management of
patients with cancer of the oesophagus and gastro-oesophageal junction in Australia. Med J Aust
2010; 193:572-577
Smithers BM. Minimally Invasive Esophgaectomy. Expert Rev Gastroenterol Hepatol
2010;4:91-99
Thomson IG, Smithers BM, Gotley DC, Martin I, Thomas J, Barbour A. Thoracoscopic assisted
esophagectomy for esophageal cancer: Analysis of patterns and prognosis factors for recurrence.
Ann Surg 2010;252:281-291
Foote MC, Burmeister BH, Thomas J, Smithers BM. A novel treatment for metastatic
melanoma with intralesional rose Bengal and radiotherapy: a case series. Melanoma Res
2010;20:48-51
Barbour AP, Thomas J, Suffolk J, Beller E, Smithers BM. Isolated limb infusion for malignant
melanoma: Predictors of response and outcomes. Ann Surg Oncol 2009;16:3463-3472
Shenfine J, Barbour AP, Wong D, Thomas J, Martin I, Gotley DC, SmithersBM. Prognostic
value of maximum standardized uptake values from preoperative positron emission tomography
in resectable adenocarcinoma of the oesophagus treated by surgery alone. Dis Esophagus
2009;22:668-675
Kelly SL, Peters P, Ogg MJ, Li A, Smithers BM. Successful management of an aortoesophageal
fistula caused by a fish bone – a case report and literature review. J Cardiothoracic Surg
2009;4:21
Burmeister BH, Walpole ET, D’Arcy N, Burmeister EA, Cox S, Thomson DB, Harvey JA,
Smithers BM. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted
infusion of 5-flurouracil for esophageal cancer. Invest New Drugs 2009;27:275-279
Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI, Clouston AD,
Hayward NK & Whiteman DC. Genome-Wide Copy Number Analysis in Esophageal
Adenocarcinoma Using High- Density Single-Nucleotide Polymorphism Arrays. Cancer Res
2008;68:4163-4172
Baxi S, Burmeister BH, Harvey J, Smithers BM. Salvage definitive chemoradiotherapy for
locally recurrent oesophageal cancer after primary surgery: Retrospective review. J Med Imaging
Radiat Oncol 2008;52:1-5
Smith E, DeYoung NJ, PAvey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM,
Rieszkewicz AR, Clouston AD, Gotley DC, Devitt PG, Jameison GG, Drewe PA. Similarity of
abberant DNA methylation in Barrett’s oesophagus and oesophageal adenocarcinoma. Molecular
Cancer 2008;7:75
Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers
BM. Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment
response. Ann Surg Oncol 2008;15:2894-2902
Foote MC, Burmeister B, Burmeister E, Bayley G, Smithers BM. Desmoplastic melanoma: The
role of radiotherapy in improving local control. ANZ J Surg 2008;78:273-276.
Shenfine J, Barbour A, Martin I, Smithers BM, Gotley DC. Letters and Comments:
Consideration of mesh-related complications. Ann R Coll Surg Engl 2008;90:175
Whiteman DC Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb PM, Green AC
for the Australia Cancer Study. Combined effects of obesity, acid reflux and smoking on the risk
of adenocarcinoma of the oesophagus. Gut 2008;57:173-80
Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson
DB, Walpole ET, Watts N, Burmeister BH. Positron emission tomography and pathological
reponse to neoadjuvant therapy in adenocarcinoma of the oesophagus. Dis Esophagus
2008;21:151-8.
Smithers BM, Gotley DC Response to letter re: Comparison of outcomes between open and
minimally invasive esophagectomy. Ann Surg 2008;247:397-8
Mark B. Commentary: Randomized clinical trial of the effects of perioperative use of immuneenhancing enteral formula on metabolic immunological status in patients undergoing
esophagectomy. World J Surg 2007; 31:2158-2159. (note – journal misprint of my name in
published article)
Burmeister BH, Walpole E, Thomas J, Smithers BM. Two cases of oesophageal carcinoma
following corrosive esophagitis successfully treated with chemoradiation therapy. Asia Pacific J
Clin Oncol 2007;3:108-111
Smithers BM, Cullinan M, Thomas JM, Martin I, Barbour AP, Burmeister BH, Harvey J,
Thomson DB, Walpole E, Gotley DC. Outcomes from salvage esophagectomy post definitive
chemoradiotherapy compared with resection following preoperative neoadjuvant
chemoradiotherapy. Dis Esophagus 2007;20:471-77
Smithers BM, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open
and minimally invasive esophagectomy. Ann Surg 2007;245:232-240
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from
neoadjuvant chemoradiation treatement and chemotherapy in oesophageal carcinoma: a metaanalysis. Lancet Oncol 2007;8:226-34.
Daly TA, Burmeister BH, Smithers BM, Doody J, Kane A. Radiotherapy for metastatic
melanoma presenting in pregnancy. Aust Radiol 2006;50:598-603.
Burmeister B,H, Smithers BM, Burmeister E, Baumann K, Davis S, Krawitz H, Johnson C,
Spry N. A prospective phase II study of adjuvant postoperative radiation therapy following nodal
surgery in malignant melanoma – Trans Tasman Radiation Oncology Group (TROG) Study
96.06. Radiother Oncol 2006;81:136-142
Coory M, Smithers M, Aitken J, Baade P, Ring I. Urban-rural differences in survival from
cutaneous melanoma in Queensland. ANZ J Population Health 2006:30;71-74
Leibman S, Smithers BM, Gotley DC, Martin I, Thomas J. Minimally invasive esophagectomy:
short and term outcomes. Surg. Endoscopy 2006:20;428-33.
Coory M, Baade P, Aitken J, Smithers BM, McLeod GR, Ring I. Trends for in-situ and invasive
melanoma in Queensland, Australia, 1982 – 2002. Cancer Causes and Control 2006:17;21-27.
Smithers BM. Commentary: A novel approach to oesophageal resection. ANZ J Surg 2005;75:
1029.
Smith L, Moore T, Smithers M, Prins J, O’Moore-Sullivan T. Effect of alpha-glucosidase
inhibition on dumping syndrome. Aust NZ J Surg. 2005:75;1124-1126.
Burmeister BH, Walpole ET, Burmeister EA, Thomas J, Thomson D, Harvey JA, Smithers BM,
Gotley DC. Feasibility of chemoradiation therapy with protracted infusion of 5-fluro-uracil for
esophageal cancer patients not suitable for cisplatin. Int J Clin Oncol 2005;10:256-261.
Smith KJ, O’Brien SM, Smithers BM, Gotley DC, Webb PM, Green AC, Whiteman DC for
Study of Diseases of Digestive Health. Interactions among smoking, obesity, symptoms of acid
refulx in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2005;14:2481-2486.
Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley
DC, Joseph D, Millar J, North J, Walpole E, Denham J. A randomised phase III study
comparing surgery alone with chemoradiation therapy followed by surgery for resectable
carcinoma of the oesophagus: an intergroup study of the Trans-Tasman Radiation Oncology
Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Lancet Oncol
2005:6:659-668.
Burmeister BH, SmithersBM. Neoadjuvant chemoradiotherapy in resectable oesophageal cancer
– Authors reply. Lancet Oncol 2005;6:825-826.
Byrne JP, Smithers BM, Nathanson LK, Martin I, Ong HS, Gotley DC. Symptomatic and
functional outcome after laparoscopic reoperation for failed antireflux surgery. Br J Surg
2005;92:996-1001.
Harvey JA, Bessell JR, Beller E, Thomas J, Gotley DC, Burmeister BH, Walpole ET, Thomson
DB, Martin I, Doyle L, Burmeister E, Smithers BM. Chemoradiation therapy is effective for the
palliative treatment of malignant dysphagia. Dis Esophagus: 2004:17;260-65.
Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Burmeister B, Harvey J, Walpole E,
Thomson D, Smithers BM. Assessing the response of oesophageal carcinoma to neoadjuvant
therapy using oesophagogastroscopy. Br J Surg 2004:91;199-204.
Stowasser M, Gordon RD, Gunaseker TG, Cowley DC, Ward G, Archibald C, Smithers BM.
High rate of detection of primary aldosteronism, including surgically treatable forms, following
“non-selective” screening of hypertensives attending a recently established Hypertension Unit. J
Hypertension 2003;21:2149-2157.
Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister BH, Lamb DS, Joseph D, Delaney
G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E. Do relapse patterns alter
following chemoradiation for carcinoma of the oesophagus? Clin Oncology 2003;15:98-108
Smithers M, O’Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabber
I, Barker K, Grimmett K, Walpole E, Thomas R. Clinical response after intradermal immature
dendritic cell vaccination in metastatic melanoma is associated with immune response to
particulate antigen. Cancer Immunol Immumother 2003; 52: 41-52.
Matheson BJ, Burmeister BH, Smithers BM, Gotley D, Harvey JA, Doyle L. Second primary
oesophageal cancer following radiation for breast cancer. Radiat Oncol 2002; 65: 159- 163.
Burmeister BH, Baumann KC, Smithers BM et al. Radiation therapy following nodal surgery
for melanoma: An analysis of toxicity. ANZ J Surg. 2002; 72: pp344-8
Ong HS, Smithers BM. Epidemiology of gastric Cancer in Australia. Gastric Cancer 2002; 5:
118-121.
Bessell JR, Adair WD, Smithers BM, Martin I, Menzies B, Gotley DC. Early reoperation for
acute dysphagia following laparoscopic fundoplication. Brit. J Surg. 2002; 89: 783 - 786.
Belt PJ, Smithers M, Elston T. The triad of bilateral retinoblastoma, dysplastic naevus syndrome
and multiple cutaneous malignant melanomas: a case report and review of the literature.
Melanoma Res 2002; 12: 179-82.
Burmeister BH, Harvey J, Smithers BM, Gotley DC. The localisation of small esophageal
cancers for radiation planning using endoscopic contrast injection- A report on a series of eight
cases. Dis Esophagus 2001;14:28-31.
Thomas R, Padmanabha J, Chambers M, McFadyen S, Walpole E, Nielssen G, Smithers BM.
Metastatic lesions in the joint associated with acute inflammatory arthritis after dendritic cell
immunotherapy for metastatic melanoma. Melanoma Res 2001; 11: 167-173.
Thompson JK, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD,
Roberts MS. Microdialysis and response during regional chemotherapy by isolated limb infusion
of melphalan for limb malignancies. Br J Cancer 2001; 79: 1-9.
Smithers BM, Gotley DC, Martin I, Bessell J, McEwan D, Doyle L. Thoracoscopic mobilisation
of the esophagus: A six year experience. Surg Endosc 2001;15:176-182.
Roberts MS, Wu ZY, Siebert GA, Anissimo YG, Thompson JF, Smithers BM.
Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent
localised limb malignancy. Melanoma Res. 2001;11:3.
Wu ZY, Smithers BM, Anderson C, Roberts MS. Can tissue drug concentrations be monitored
by microdialysis during or after isolated limb perfusion for melanoma treatment? Melanoma Res
2000;10:47-54.
Bessell JR, Finch R, Gotley DC, Smithers BM, Nathanson L, Menzies B. Chronic dysphagia
following laparoscopic fundoplication. Brit. J. Surg. 2000;87:1341-1345
Burmeister BH, Dickie G, Smithers BM, Hodge R, Morton K. Thirty-four patients with
carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch. Otolaryngol.
Head Neck Surg. 2000; 126: 205-208.
Thomas R, Chambers M, Boytar R, Barker K, Cavanagh L, MacFadyen S, Smithers M, Jenkins
M, Andersen J. Immature human monocyte-derived dendritic cells migrate rapidly to draining
lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res.1999;
9:474-481
Martin I, O’Rourke N, Gotley D, Smithers M. Laparoscopy in the management of
diaphragmatic rupture due to blunt trauma. Aust NZ J Surg. 1998; 68: 584-586
Burmeister BM, Smithers BM, Denham JW. Combined modality therapy for carcinoma of the
oesophagus: current status and future direction. MJA 1997; 167: 349-350
Roberts MS, Wu ZY, Rivory LP, Smithers BM, Egerton WS, Weiss M. Relative dispersion of
intravascular transit times during isolated limb perfusion for recurrent melanoma. Br J Clinical
Pharmacol 1997; 44: 347-351
Wu ZY, Smithers BM, Roberts MS. Tissue and perfusate pharmacokinetics of melphalan in
isolated perfused rat hindlimb. J Pharm and Exp Theurap 1997; 282: 1131-1138
Smithers BM, Devitt P, Jamieson GG, Bessel J, Gotley D, Gill PG, Neely M, Joseph DJ, Yeoh
EK, Burmeister B, Denham JW. A combined modality approach to the management of
oesophageal cancer. Eur. J. Surg. Oncol. 1997; 23: 219-223
Wu ZY, Smithers BM, Parsons P, Roberts MS. Effects of perfusion conditions on melphalan
tissue distribution in isolated perfused rat hindlimb bearing a human melanoma xenograft. Brit. J.
Cancer 1997; 75: 1160-1166.
Wu ZY, Smithers BM, Roberts MS. Melphalan dosing-regimens for management of recurrent
melanoma by isolated limb perfusions: application of a physiological pharmacokinetic model
based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Research 1997;
7: 252-264
Wu, ZY, Roberts, MS, Parsons PG, Smithers BM. Isolated limb perfusion with melphalan for
human melanoma xenografts in the hind limb of nude rats: a surviving model. Melanoma
Research 1997; 7: 19-26.
Gotley DC, Smithers BM, Menzies B, Branicki FJ, Rhodes M, Nathanson L. Laparoscopic
Nissen Fundoplication and Post-operative Dysphagia - Can it be Predicted? Ann Acad Med
Singapore 1996; 25: 646-649.
Gotley DC, Rhodes M, Smithers BM, Branicki F, Menzies B, Nathanson L. Laparoscopic
Nissen's fundoplication - 200 consecutive cases. Gut 1996; 78: 487-491.
Hansen J, Smithers BM, Schache D, Wall D, Miller BJ, Menzies B. Prospective randomized
trial of laparoscopic versus open appendicectomy for acute appendicitis. World J Surg 1996; 20:
17-21.
Smithers BM, Theile DE, Dickinson IC, Thomson DB, Axelsen RA. Malignant sacrococcygeal
germ cell tumour in an adult. Aust & NZ J Surg 1996; 66: 185-189.
Kelly B, Raphael B, Smithers BM, Swanson C, Reid C, Thomson D, Walpole E, McLeod R.
Psychological responses to malignant melanoma: an investigation of traumatic stress reaction in
life-threatening illness. Gen Hosp Psychiatry 1995; 17: 126-134.
Selvey L, Hogan P, Frazer IH, Smithers BM, Robinson D. HIV testing before surgery (letter).
Aust J Public Health 1995; 19: 107-108.
Wu, ZY, Thompson, MJ, Roberts, MS, Grabs, AJ, Smithers, BM, Addison, RS, Conell, GR.
High performance liquid chromatographic assay for the measurement of melphalan and its
hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat
isolated into perfusion. J Chromat B, 1995; 673: 267-279.
Burmeister B, Smithers BM, Bryant G, McLeod GR. Radiation therapy for nodal disease in
malignant melanoma. World J Surg 1995; 19: 369-371.
Clark J, Grabs AJ, Smithers BM, Roberts MS, Parsons P. Melphalan uptake hyperthermic
synergism and drug resistance in a human cell model for the isolated limb perfusion of
melanoma. Melanoma Research 1994; 4: 365-370.
Nicol DL, Smithers BM. Laparoscopic approach to the left kidney avoiding colonic
mobilization. J. Urol. 1994; 152: 1967-1969.
Lange B, Harper J, Smithers BM. Percutaneous fluoroscopic gastrostomy. A safe option. Med
J Aust 1994; 161: 308-310.
Nicol DL, Winkle DC, Nathanson LK, Smithers BM. Laparoscopic Nephrectomy for benign
renal disease. Brit J Urology 1994; 73: 237-241.
Kastrissios H, Triggs ES, Sinclair F, Moran P, Smithers M. Plasma concentrations of
bupivacaine after wound infiltration of an 0.5% solution after inguinal hemiorrhaphy: a
preliminary study. Eur J Clin Pharmacol 1993; 44: 555-557.
Nathanson LK, Gotley D, Smithers BM, Branicki F. Video-thorascopic primary repair of early
distal oesophageal perforation. Aust & NZ J Surg 1993; 63: 399-403.
Walker NI, Smith MM, Smithers BM. Ultrastructure of human Melanosis coli with reference to
its pathogenesis. Pathology 1993; 25: 120-123.
Smithers BM, McLeod GR, Little JH. Desmoplastic melanoma - Patterns of recurrence. World
J Surg 1992; 16: 186-190.
Green MK, Smithers BM, Moran JE. A Comparison of Techniques for Isolation of Mouse
Islets. Transplant Proc 1992; 24: 235-236.
Smithers BM, O'Loughlin B, Strong RW. Diagnosis of ruptured diaphragm following blunt
trauma. Results from 85 cases. Aust NZ J Surg 1991; 61: 737-741.
Theile DE, Smithers BM, Windsor JC, Strong RW. Primary adenocarcinoma in a colonic
"oesophageal segment". Aust NZ J Surg 1991; 61: 953-955.
Smithers BM, McLeod GR, Little JH. Desmoplastic, neural transforming and neurotropic
melanoma - A clinico-pathological review of 45 cases. Aust NZ J Surg 1990; 60: 967-972.
Reasbeck PG, Smithers BM, Blackley P. Construction and management of ileostomies and
colostomies. Dig Dis 1989; 7: 265-280.
Ross WB, Tweedie J, Leong YP, Wyman A, Smithers BM. Intercostal blockade and pulmonary
function after cholecystectomy. Surgery 1989; 105: 166-169.
Geroulakos G, Taylor W, Smithers BM, Wilkins JL. Multiple enteroliths in a chronically
obstructed duodenal loop after Roux en Y Biliary Diversion. Surgery 1987; 102: 883-885.
Ross WB, Tweedie J, Leong YP, Wyman A, Smithers BM. Does intercostal blockade improve
patient comfort after cholecystectomy. Brit J Surg 1987; 74: 63.
Smithers BM, Cooksey G, Foster M, Blamey R. The availability of organs for transplantation:
A three-year study. BMJ 1986; 293: 923.
Smithers BM, Theile D, Cohen J, Evans E, Davis NC. Emergency right hemicolectomy in colon
carcinoma: A prospective study. Aust NZ J Surg 1986; 56: 749-752.
Smithers BM, Welch C, Goodall P. Cystadenocarcinoma of the pancreas presenting in
pregnancy. Brit J Surg 1986; 73:591.
Smithers BM, Myers PT. Injuries in sport: A prospective casualty study. Med J Aust 1985;
142:457-461.
Smithers BM, Wall D, Weedon D. Actinomycosis of the gall bladder. Aust NZ J Surg 1983;
587-588.
PUBLISHED ABSTRACTS
(54)
Grob JJ, Santinami M, Trefzer U, Robert C, Smithers B, Mortier L, Levchenko E, Demidov L,
Jouary T, Grange F, Testori A, Thompson J, Peeters O, Dreno B, Kirkman JM. Expression of
MAGE-A3 among stage IIIB-C melanoma patients: preliminary results of screening tests for the
DERMA trial. Pigment Cell Melanoma Res 2010;23:891
Agarwala S, Thompson J, Smithers BM, Ross MI, Coventry BJ, Minor DR, Scoggins C,
Wachter EA. Chemoablation of metastatic melanoma with intralesional PV-10. Pigment Cell
Melanoma Res 2010;23:883
Shafren DR, Hersey P, Smithers M. Phase I evaluation of intralesional administration of
oncolytic Picovirus, Coxsackievirus A21 (CAVATAKTM) in patients with late stage melanoma.
Pigment Cell Melanoma Res 2010;23:883
Smithers BM, Corish T, Moore S, Fahey P, Whiteman. Oesophageal cancer: outcomes from
surgery in Australia 2003-05. Aust NZ J Surg 2010;80(suppl. 1):A96
Smithers BM, Burmeister B, Walpole E, Gotley D, Harvey J, Thomas J. Is radiation required in
patients having preoperative chemotherapy for adenocarcinoma of the oesophagus? A
randomized phase II trial. Aust NZ J Surg 2010;80(suppl. 1):A96
Hirst J, Smithers M, Gotley D, Martin I, Thomas J, Barbour A. Minimally invasive
oesophagectomy: health related-quality of life outcomes. Aust NZ J Surg 2010;80(suppl. 1):A96
Mackrill D, Kan YK, Stabler A, Smithers MB. Acute appendicitis, does the laparoscopic
operation lead to more complications? Aust NZ J Surg 2010;80(suppl. 1):A33
Thomson IG, Waters B, O’Rourke P, Barbour A, Smithers M, Gotley D. Postoperative
nomogram for disease specific survival after surgery for oesophageal cancer. ANZ J Surg
2009;79(suppl 1):A41
Hirst J, Smithers M, Gotley D, Martin I, Thomas J, Barbour A. Actual 5-year survival following
oesophagectomy and predictors of survival. ANZ J Surg 2009;79(suppl 1):A41
Duong C, Smithers M, Thomas J, Gotley D, Martin I, Barbour A. Evolving management of high
grade dysplasia in Barrett’s oesophagus. ANZ J Surg 2009;79(suppl 1):A42
Frankel AJ, Smithers BM, Thomas J, Barbour A, Bayley G. Morbidity of regional lymph node
surgery for cutaneous melanoma. ANZ J Surg 2009;79(suppl 1):A80
Smithers BM, Doecke J, Corish T, Moore S, Whiteman D. Oesophageal Cancer: Patterns of
Care in Australia. Asia Pacific J Clin Oncol 2008;4:Supp2, A30.
Whiteman D, SmithersBM, Gotley DC, Pandeya N, Sadeghi S, Green AC, Webb PM. The
epidemiology of oesophageal cancer. Asia Pacific J Clin Oncol 2008;4:Supp2, A42.
Burmeister BH, Smithers BM, Thomas J, Burmeister E, Walpole E, Harvey J, Thomson D,
Barbour A, Gotley D. A ranodomised phase II trial comparing pre-operative chemotherapy with
pre-operative chemoradiation therapy for localized carcinoma of the oesophagus. Asia Pacific J
Clin Oncol 2008;4:Supp2, A47
Thompson JF, Hersey P, Smithers BM, Coventry B, Ross MI, Wachter E. Chemoablation of
cutaneous and subcutaneous metastatic melanoma using PV-10. Asia Pacific J Clin Oncol
2008;4:Supp2, A72
Baumgartner L, Vivanti A, Smithers M. Jejunally fed patients post oesophagectomy /
gastrectomy – are they getting all they need? – An audit at the Princess Alexandra Hospital. Asia
Pacific J Clin Oncol 2008;4:Supp2,A107
Barbour A, Thompson I, Gotley DC, Jones M, Thomas J, Martin I, Smithers MB. Minimally
invasive esophagectomy for esophageal cancer: analysis of recurrence patterns and prognostic
factors of recurrence. Asia Pacific J Clin Oncol 2008;4:Supp2, A116
McFadyen, Herlaar H, Smithers M. Melanoma Patients Australia – A focus on patient support
and advocacy. Asia Pacific J Clin Oncol 2008;4:Supp2, A147
Hughes A, Smithers BM, Thomas J, Martin I, Gotley DC, Barbour AP. Surgery for early
adenocarcinoma: Analysis of lymphatic spread and prognostic factors. Ann Surg Oncol 2007;2
(supp): 103 (P237).
Barbour AP, Smithers BM, Gotley DC, Thomas J, Burmeister B, Thomson D. Refining
oesophageal cacner staging after neoadjuvant therapy: Importance of primary tumour response.
Aust NZ J Surg 2006:76(suppl. 1); A39.
Barbour AP, Smithers BM, Gotley DC, Thomas J, Burmeister B, Walpole E. Patterns and
predictors of initial recurrence following resection for adenocarcinoma of the oesophagus and
gastro-oesophageal junction. Aust NZ J Surg 2006:76 (suppl. 1); A40.
Barbour AP, Beller E, Smithers BM. Isolated Limb Infusion (ILI) for Malignant Melanoma:
Predictors of response and outcome. Ann Surg Oncol 2006; 13 (suppl):51
Burmeister BH, Smithers BM, Burmeister EA, Baumann KC, Davis SR, Krawitz H, Johnson C,
Spry N. A prospective phase II study of postoperative radiation therapy following nodal surgery
for malignant melanoma – trans tasman radiation oncology group (trog) study 96.06. AsiaPacific J Clin Oncol 2005;1 (suppl.): A26.
Burmeister BH, Smithers BM. Preoperative adjuvant chemoradiation therapy for localized
oesophageal cancer – study 9401 and the aftermath. Asia- Pacific J Clin Oncol 2005;1 (suppl.):
A26.
Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Burmeister B, Harvey J, Walpole E,
Thomson D, Smithers BM. Assessing the response of oesophageal carcinoma to neoadjuvant
therapy using oesophagogastroscopy. Aust NZ J Surg 2003: 72 (suppl);A63.
Lim KH, Thomas J, Brown WA, Harvey J, Burmeister B, Walpole E, Thomson D, Martin I,
Gotley DC, Smithers BM. A comparison of treatment outcome between adenocarcinoma and
squamous cell carcinoma of the oesphagus. Aust NZ J Surg 2003: 72 (suppl);A63.
Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Smithers BM. The role of surgery in the
management of locally advanced oesophageal carcinoma. Aust NZ J Surg 2003: 72 (suppl);A63.
BM Smithers, Burmeister BH, L Fitzgerald, V Gebski, P Devitt, S Ackland, D Joseph, J Millar,
J North, E Walpole, D. Gotley. A randomized phase III trial of surgery alone compared with
chemoradiation & surgery: a focus on the surgical outcomes. Ann Surg Oncol 2003:
10(suppl);S10
BH Burmeister, BM Smithers, L Fitzgerald, V Gebski, P Devitt, S Ackland, D Joseph, J Millar,
J North, E Walpole, JW Denham. A randomized phase III trial of preoperative chemoradiation
followed by surgery versus surgery alone for localized respectable cancer of the oesphagus. Proc
ASCO 2002: 21;130a. abstract
J.R.Bessell, R.Finch, D.C.Gotley, B.M.Smithers, L.Nathanson, L.Doyle, B.Menzies. Chronic
dysphagia following laparoscopic fundoplication. Brit J Surg 2000;87 (Suppl 1):32.
Smithers BM, Burmeister B, Baumann K. Phase II study assessing the role of radiotherapy after
nodal surgery for metastatic melanoma. Aust NZ J Surg 2000:70(supp);A78
Gotley DC, Smithers BM, Martin I, Sanders G, Doyle LM. Barrett’s oesophagus: natural history
and surveillance. Aust NZ J Surg 2000:70(supp);A89
Gotley DC, Smithers BM, Martin I, Bessell J, Doyle LM. Laparoscopic versus open surgery for
oesophageal cancer. Aust NZ J Surg 2000:70(supp);A93
Smithers BM, Gotley DC, Doyle LM. Oesophageal cancer: Neoadjuvant therapy. Aust NZ J
Surg 2000:70(supp);A93
Gotley DC, Smithers BM, Martin I, Bessell J, Doyle L, Menzies B, Nathanson L. Elective
laparoscopic fundoplication for reflux: 1000 consecutive cases with 1-5 year follow-up. J. Gastro
Hepatol 1999: 14(supp); A144
Sanders G, Smithers BM, Gotley DC, Clouston A. High Grade Dysplasia in Barrett’s
Oesophagus. J Gastro Hepatol 1999: 14(supp); A157
Bessell JR, Smithers BM, Gotley DC, Martin I, Harvey J, Burmeister B, Walpole E, Thomson
D, Doyle L. The role of chemo-radiotherapy prescribed by a multi-disciplinary team for the
palliative treatment of malignant dysphagia. J Gastro Hepatol 1999: 14(supp); A206
Ackland S, Burmeister BH, Smithers BM, Devitt P, Woods S, Gillies J, Walpole E, Findley M,
Gray E, Denham J. Preoperative chemoradiation (CT/RT) versus surgery alone for resectable
carcinoma of the oesophagus: An Australian randomised study. Proc. ASCO 1998, 17; 285a
Juffs HG, Thomson DB, Walpole ET, MacKintosh JF, Burmeister BH, Harvey JA, Smithers
BM, Gotley DC. Retrospective Analysis of Concurrent Radiation and 5-Flurouracil (5FU)
Alone for Oesophageal Cancer. Proc. ASCO 1998; 17: 293a .
Smithers BM, McLeod GRC, Anderson J, Strutton K. Establishing selective lymphadenectomy
for cutaneous melanoma. Aust N.Z. J Surg. 1997; 67 (Supp): A33.
Smithers BM, Gotley DC, Smith C. Thoracoscopic oesophageal mobilisation for carcinoma.
Aust N.Z. J Surg. 1997; 67 (Supp): A45.
Gotley DC, Smithers BM, Menzies B, Nathanson L. Successful application of laparoscopy to
correction of gastro-oesophageal reflux. Aust N.Z. J Surg. 1997; 67 (Supp): A46.
Burmeister BH, Poulsen MG, Smithers BM, McLeod GR, Harvey JA, Morton K. Radiation
therapy following nodal dissection for malignant melanoma: a report on a phase II study.
Melanoma Res. 1997; 7 (Supp): S18.
Harvey JA, Burmeister BH, Smithers BM, McLeod GR. Metastatic malignant melanoma to the
orbit: a report of nine cases. Melanoma Res. 1997; 7 (Supp): S115.
Smithers BM, McLeod GR, Anderson J, Strutton G. The trials and tribulations of establishing
selective lymphadenectomy for cutaneous melanoma. Melanoma Res. 1997; 7 (Supp): S120.
Smithers BM, Wu ZY, Parsons, PG, Roberts MS. The use of an animal model to explore
conditions for isolated limb perfusion. Melanoma Res. 1997; 7 (Supp): S121.
Wu ZY, Smithers BM, Roberts MS. Melphalan dosing regimens for the management of
recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic
model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Res.
1997; 7 (Supp): S121.
Rhodes M, Gotley DG, Smithers BM, Menzies B, Branicki FJ, Nathanson LK. Laparoscopic
Nissen fundoplication: lessons learned from 200 consecutive cases. Gut. 1995; 36 (Supp): A28.
Smithers BM, Hansen J, Schache D, Wall D. Prospective randomized trial of laparoscopic
versus open appendicectomy for acute appendicitis. Surg Endosc 1994; 8:565.
Nicol DL, Smithers BM. Laparoscopic Nephrectomy for benign renal disease. Surg Endosc
1994; 8:557.
Smithers BM, Gotley DC. Thoracoscopic mobilization of the oesophagus in three stage
oesophagectomy. Surg Endosc 1994; 8:490.
Grabs AJ, Smithers BM, Parsons P, Clark J, Roberts MS The influence of hypothermia on
multiple melanoma cell lines treated with melphalan Aust NZ J Surg 1994; 64: 358-359.
Walpole ET, Beadle GF, McLeod GR. High dose tamoxifen does not enhance the activity of
dacarbazine in metastatic melanoma. QMP 9105. Proc Am Soc Clin Oncol 1993
Wu ZY, Addison RS, Smithers BM, Roberts MS. The effects of perfusate conditions on the
stability of melphalan in rat isolated limb perfusion. Clin Exp Pharmacol Physiol: (Supp)
1993;80.
Ross WB, Tweedy JH, Yeong YP, Wyman A, Smithers BM Intercostal blockade and
pulmonary function after cholecystectomy. Current Surgery 1989; 46: 410.
BOOK CHAPTERS
Smithers BM. Primary Melanomas of the Gastrointestinal Tract. In “Textbook of Melanoma”
Ed Thompson J, Morton D, Kroon B. Pub: Martin Dunitz, London, England. 2004: 648-662.
Smithers BM, deWilt J. Isolated limb perfusion and infusion: preclinical studies and future
directions. In “Textbook of Melanoma” Ed Thompson J, Morton D, Kroon B. Pub: Martin
Dunitz, London, England 2004:438-442.
Burmeister BH, Poulsen M, Smithers BM, Kennedy D, Thompson D. Skin and Melanoma
Cancer. Ch 16, UICC Manual of Clinical Oncology, 8th Edition, 2002
Burmeister BH, Poulsen M, Smithers BM, Kennedy D, Thompson D. Skin and Melanoma
Cancer. Ch 16, UICC Manual of Clinical Oncology, 7th Edition, 1999
BOOK REVIEWS
Acute Gastro-intestinal Bleeding. Diagnosis and Treatment. Aust NZ J Surg. 2005;75:474
OTHER PUBLICATIONS
Debate – Gastroesophageal reflux disease: Zap, Sew or Wrap. Wrap: Laparoscopic
fundoplication. Mark Smithers. Asia Pacific Digestive News. 2002;9:12.
Guidelines for the Management of Melanoma 1998 - Member of the Advisory Group who
developed the document. This is now an NH&MRC guidelines book.
Clinical Practice Guidelines for the management of Melanoma 2008 – Member of the
developmental working party. Chapter leader – “Appropriate Investigations”
EDITORIAL BOARDS
Asia Pacific Journal of Surgery 2008 - present
British Journal of Surgery 2008 - present
World Journal of Surgery 2009 - present
Australian and New Zealand Journal of Surgery 2008 – present
JOURNAL REVIEWS
Australian and New Zealand Journal of Surgery
British Journal of Surgery
World Journal of Surgery
Oncology
Journal of the American College of Surgeons
Annals of Surgical Oncology
Future Oncology
Diseases of the Esophagus
European Journal of Surgical Oncology
PRESENTATIONS AT CONFERENCES AND MEETINGS: 1997 - 2010
# International Meeting
2011
Invited Presentations
Clinical trials in melanoma at the Princess Alexandra Hospital
International Skin Cancer Research Workshop, Brisbane, March 2011
2010
Invited Presentations
Outcomes from Minimally Invasive Oesophagectomy
The role of salvage chemoradiation following recurrence of oesophageal cancer
Preoperative chemotherapy or chemoradiation for gastric cancer.
#The 3rd MATTU Oesophago-Gastric Cancer Symposium, Guildford, England
Diagnosis of Barrett’s Oesophagus and results of management of intramucosal adenocarcinoma
of the oesophagus.
Minimally invasive oesophageal resection for middle third cancers
#3rd Asia Pacific Gastro-esophageal Cancer Congress, Kuala Lumpur, Malaysia
The burden of follow up for melanoma.
#4th Melanoma and Skin Cancer Centres Meeting, Sydney, Australia
Minimising operative mortality following oesophagectomy
#Australian and New Zealand Gastro-Oesophageal Surgeons Association Annual Scientific
Meeting, Queenstown, New Zealand.
Outcomes from Minimally Invasive Esophagectomy.
New approaches to staging esophageal cancer
#International Society for the Diseases of the Esophagus, Kagoshima, Japan
The emerging role of PET scanning in oesophageal cancer.
The management of local and in-transit recurrence of cutaneous melanoma.
Annual Scientific Congress, Royal Australiasian College of Surgeons, Perth, Australia
Outcomes from Laparoscopic Hiatal Surgery.
Cairns Gut Club, Cairns, Australia
Improving outcomes from Oesophageal cancer
Townsville Gut Club.
Reviewed presentations.
Phase I evaluation of intralesional administration of oncolytic Picovirus, Coxsackievirus A21
(CAVATAKTM) in patients with late stage melanoma. DR Shafren, P Hersey, M Smithers
Chemoablation of metastatic melanoma with intralesional PV-10. S Agarwala, J Thompson, BM
Smithers, MI Ross, BJ Coventry, DR Minor, CR Scoggins, EA Wachter.
Expression of MAGE-A3 among stage IIIB-C melanoma patients: preliminary results of
screening tests for the DERMA trial. JJ Grob, M Santinami, U Trefzer, C Robert, B Smithers, L
Mortier, E Levchenko, L Demidov, T jouary, F Grange, A Testori, J Thompson, O Peeters, B
Dreno, JM Kirkman.
4th Melanoma and Skin Cancer Centres Meeting, Sydney, Australia
Oesophageal cancer: Outcomes from surgery in Australia 2003-05. BM Smithers, T Corish, S
Moore, P Fahey, D Whiteman.
Is radiation required in patients having preoperative chemotherapy for adenocarcinoma of the
oesophagus? A randomized phase II trial. BM Smithers, B Burnmeister, E Walpole, D Gotley, J
Harvey, J Thomas.
Minimally invasive oesophagectomy: health related-quality of life outcomes. J Hirst, M
Smithers, D Gotley, I Martin, JThomas, A Barbour.
Acute Appendicitis, does the laparoscopic operation lead to more complications. D Mackrill, Y
Kan, A Stabler, M Smithers
Annual Scientific Congress, Royal Australiasian College of Surgeons, Perth, Australia
DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III
melanoma: MAGE-A3 gene expression frequency and baseline demographics.
Trefzer V, Jovary T, Robert C, Santinami M, Levchenko E, Smithers B, Testori A, Peeters A,
Kirkwood J, Dreno B.
6th Congress of the European Association of Dermo-Oncology, June 2010
2009
Invited Presentations
 Clinical and Translational Research.
Developing an Academic Career in Surgery Workshop. Royal Australiasia College of
Surgeons, Brisbane, Australia
 Oesophageal Cancer – the role of surgery.
Radiation Oncology Trainees Weekend, Gold Coast, Australia.
 The role of radiation for resectable oesophageal cancer - A debate.
The Australasian Gastro-intestinal Trials Group, Brisbane, Australia
 Patient selection and outcomes for resection for HGD and intramucosal oesophageal cancer.
The role of follow up after resection for oesophageal cancer
Australian Gastro-enterology Week, Sydney, Australia
 Cutaneous melanoma: incidence, diagnosis, staging and latest treatment options
Consumer Forum, Melanoma Patients Australia, Townsville, Australia.
2008
Invited Presentations
 Video presentation of Revision fundoplication
Seminars in Operative Surgery, Adelaide, Australia
 The role of surgery for GIST
North Coast Cancer Conference, Kingscliff, Australia
 Revision Fundoplication
 Minimally invasive oesophagectomy
#International Society of Surgery conference, Townsville, Australia
 The outcomes form treating Achalasia
 Quality of life of anti-reflux surgery
 Minimally invasive surgery and mid oesophageal cancers
 Does surgical technique influence outcome in oesophageal cancer
 Oesophageal cancer: the last 20 years and 20 years into the future
 Minimally invasive oesophagectomy – A masterclass
# Combined Annual Scientific Congress – Royal Australasian College of Surgeons and
College of Surgeons of Hong Kong. – Distinguished Invited Visitor
 The role of neoadjuvant therapy for oesophageal cancer.
5th Sino-Australian Surgical Oncology Meeting. Guangzhou, China
 The management of high grade dysplasia in Barrett’s oesophagus
Australian Gastroenterology Week, Brisbane, Australia
 The diagnosis and management of Barrett’s oesophagus
 High Grade Dysplasia in Barrett’s – EMR or Resection
 Video Presentation – Minimally invasive oesophagectomy
# 2nd Asia Pacific Gastroesophageal Cancer Congress, Hong Kong.
 The management of high grade dysplasia in Barrett’s Oesophagus
Sydney Upper GI Surgeons Society, Sydney
 Oesophageal Cancer: Patterns of Care in Australia. Smithers BM, Doecke J, Corish T, Moore
S, Whiteman D.
 The epidemiology of oesophageal cancer. Whiteman D, Smithers BM, Gotley DC, Pandeya
N, Sadeghi S, Green AC, Webb PM.
Annual Scientific Meeting of the Clinical Oncological Society of Australia, Sydney
Reviewed Presentations
 Quantitative positron emission tomography values predict prognosis in resectable
adenocarcinoma of the oesophagus. J Shenfine, A Barbour, D Wong, I Martin, J Thomas, DC
Gotley, BM Smithers
11th World Congress of the International Society for Diseases of the Esophagus, Budapest,
Hungary
 Minimally invasive esophagectomy for esophageal cancer: Analysis of patterns and prognostic
factors for recurrence. Thompson I, Smithers BM, Gotley DC, Martin I, Thomas J, Barbour A.
45th Annual Scientific Meeting, Surgical Research Society of Australia and New Zealand
 A ranodomised phase II trial comparing pre-operative chemotherapy with pre-operative
chemoradiation therapy for localized carcinoma of the oesophagus. Burmeister BH, Smithers
BM, Thomas J, Burmeister E, Walpole E, Harvey J, Thomson D, Barbour A, Gotley D.
 Chemoablation of cutaneous and subcutaneous metastatic melanoma using PV-10. Thompson
JF, Hersey P, Smithers BM, Coventry B, Ross MI, Wachter E.
Annual Scientific Meeting of the Clinical Oncological Society of Australia, Sydney
Poster presentations
 Long-term patient reported outcomes of laparoscopic oesophageal myotomy with anterior
fundoplication in patients with achalasia. J. Shenfine, L. Koval, B. Menzies, B.M. Smithers,
D.C. Gotley. (Winner of AUGIS Best Poster Presentation Prize).
 Positron emission tomography standardised uptake values predict prognosis in resectable
adenocarcinoma of the oesophagus J. Shenfine, A. Barbour, J. Thomas, D.C. Gotley,
B.M.Smithers
Association of Upper Gastrointestinal Surgeons Annual Scientific Meeting, Liverpool, UK
 Jejunally fed patients post oesophagectomy / gastrectomy – are they getting all they need? –
An audit at the Princess Alexandra Hospital. Baumgartner L, Vivanti A, Smithers M.
 Minimally invasive esophagectomy for esophageal cancer: analysis of recurrence patterns and
prognostic factors of recurrence. Barbour A, Thompson I, Gotley DC, Jones M, Thomas J,
Martin I, Smithers MB
Melanoma Patients Australia – A focus on patient support and advocacy. McFadyen, Herlaar H,
Smithers M.
2007
Invited Presentations
 The role of neoadjuvant therapy for adenocarcinoma of the esophagus
 The role of laparoscopic surgery for GIST tumours
 Video presentation of laparoscopic anti reflux surgery
 Laparoscopic repair of para-esophageal hernias
 Laparoscopic splenectomy – The gold standard?
 Trends in the management of Melanoma – the Queensland perspective.
#Combined Annual Scientific meetings of South African Gastro-enterology Society / South African Society of
Endoscopic Surgeons / Association of Surgons of South Africa, Sun City, South Africa
 Neoadjuvant therapy for oesophageal cancer – Are we there yet?
Annual Scientific Congress, Royal Australasian College of Surgeons, Christchurch, New Zealand.
Poster Presentations
 Surgery for early adenocarcinoma: Analysis of lymphatic spread and prognostic factors. Hughes A, Smithers
BM, Thomas J, Martin I, Gotley DC, Barbour AP
#60th Annual Cancer Symposium, Society of Surgical Oncology, Washington, USA
2006
Invited Presentations
 Chemoradiation for Oesophageal Cancer
 Salvage Oesophagectomy after chemoradiation.
# 10th World Congress of the International Society for Diseases of the Esophagus, Adelaide, Australia
 The present status of neoadjuvant therapy for oesphageal cancer.
Annual Scientific Congress, Royal Australasian College of Surgeons, Sydney.
Poster Presentations
 Is the quality of life improved by minimally invasive approaches to oesophagectomy?
Smithers BM, Gotley DC, Thomas J, Doyle L.
 Outcomes from Salvage oesophagectomy post definitive chemoradiotherapy compared with preoperative
neoadjuvant chemoradiation.
Cullinan M, Gotley DC, Thomas J, Martin I, Barbour A, Burmeister B, Harvey J, Thomson D, Walpole E, Smithers
BM.
# 10th World Congress of the International Society for Diseases of the Esophagus, Adelaide, Australia
 Isolated Limb Infusion (ILI) for Malignant Melanoma: Predictors of response and outcome. Barbour AP, Beller
E, Smithers BM.
# 59th Annual Cancer Symposium, Society of Surgical Oncology, San Diego, USA
 Gene promoter methylation of ID4 and ARL4D in Barrett’s esophagus and esophageal adenocarcinoma. Smith E,
Nancarrow DJ, Pavey S, Hayward NK, De Young NJ, Kelly JJ, Whiteman DC, Smithers BM, Gotley DC, Drew
PA.
#American Gastro-enterology Week
International Invitation
 Management of Cutanoeus Melanoma
 The management of Gastrointestinal stromal tumours
 Management of oesophageal cancer
General Surgery Training Day, Christchurch, New Zealand
Invited Chairmanship
 Plenary Seminar: Hot topics in Gastro-Oesophageal Reflux Disease
# 10th World Congress of the International Society for Diseases of the Esophagus, Adelaide, Australia
 The management of retroperitoneal sarcomas.
Annual Scientific Congree, Royal Australasian College of Surgeons, Sydney.
2005
Invited Presentations
 The present status of adjuvant therapy for melanoma
 The role of surgery for GIST tumours
 Future directions and prevention in management of oesophageal cancer
Annual Scientific Meeting, Royal Australasian College of Surgeons, Perth, Australia.
Referreed Presentations
 A prospective phase II study of postoperative radiation therapy following nodal surgery for malignant melanoma
– trans Tasman radiation oncology group (TROG) study 96.06
BH Burmeister, BM Smithers, EA Burmeister, KC Baumann, SR Davis, H Krawitz, C Johnson, N Spry.
 Preoperative adjuvant chemoradiation therapy for oesophageal cancer – study 9401 and the aftermath.
BH Burmeister, BM Smithers
32nd Annual Scientific Meeting of the Clinical Oncological Society of Australia, Brisbane, Australia.
 Trends for in-situ and invasive melanoma in Queensland, Australia, 1982 to 2002
Coory M, Baade P, Aitken J, Smithers BM, McLeod GR, Ring I.
#6th World Congress on Melanoma, Vancouver, Canada
Poster Presentation
 Survival in Queensland from cutaneous invasive melanoma 1982-99 – A population study.
Smithers BM, Coory M, Baade P, Aitken J, McLeod GR, Ring I.
#6th World Congress on Melanoma, Vancouver, Canada
2004
Invited Presentations
 The role of chemoradiation for locally advanced oesophageal cancer
Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne
 Practical management of Primary Melanoma
Skin Cancer Workshop, General Practice Group, Gold Coast.
 The present status of adjuvant therapy for oesophageal cancer
IDSEA Meeting (International Diseases of the Esophagus, Australian Chapter),
Sydney.
2003
Refereed Presentations
• A randomized phase III trial of surgery alone compared with chemoradiation & surgery: a focus on the
surgical outcomes.
BM Smithers, Burmeister BH, L Fitzgerald, V Gebski, P Devitt, S Ackland, D Joseph,
J Millar, J North, E Walpole, D. Gotley.
56th Annual Cancer Symposium, Society of Surgical Oncology, Los Angeles, USA
•
High rate of detection of primary aldosteronism, including surgically treatable forms, associated with the
"non-selective" screening of hypertensives attending a recently established Hypertension Unit
Michael Stowasser, Richard D. Gordon, Thanuja G. Gunasekera, Diane C. Cowley,
Gregory J. Ward, Colin Archibald and B. Mark Smithers
Annual Meeting, US Endocrine Society.
 Assessing the response of oesophageal carcinoma to neoadjuvant therapy using oesophagogastroscopy.
Brown WA, Thomas J, Gotley DC, Lim KH, Martin I, Burmeister B, Harvey J, Walpole E, Thomson D,
Smithers BM.
 A comparison of treatment outcome between adenocarcinoma and squamous cell carcinoma of the
oesphagus. Lim KH, Thomas J, Brown WA, Harvey J, Burmeister B, Walpole E, Thomson D, Martin I,
Gotley DC, Smithers BM. .
 The role of surgery in the management of locally advanced oesophageal carcinoma. Brown WA, Thomas J,
Gotley DC, Lim KH, Martin I, Smithers BM.
Royal Australasian College of Surgeons, Annual Scientific Congress, Brisbane, Aust.
Invited Presentations


Laparoscopic Para-oesophageal Hernia Repair
Management of high grade dysplasia in Barrett’s oesophagus






Should we operate on locally advanced carcinoma of the oesophaus?
The management of the high risk primary melanoma
Adjuvant therapy for melanoma – a surgeon’s perspective.
Surgeons and clinical trials, are they compatible?
Oesophagogastric cancer, the role of multi-disciplinary care and the effect of experience.
Laparoscopic fundoplication for chronic cough.
John Goatcher Surgeon in Residence, Royal Perth Hospital, Perth, Aust.
 Neoadjuvant therapy for oesophageal cancer, results of recent trials.
Oncology meeting, Prince of Wales Hospital, Sydney, Australia
Invited Chairmanship
• Esophageal Cancer: Chemoradiation? Surgery? Either? Both?
Breakfast Session, 56th Annual Cancer Symposium, Society of Surgical Oncology,
Los Angeles, USA
 Multidisciplinary Tumour Board Case Discussions
 Management of gastric cancer
Royal Australasian College of Surgeons, Annual Scientific Congress, Brisbane, Aust
2002: Invited Presentations
• Debate: “The role of Laparoscopic Appendicectomy”
• “Oesophageal Cancer – Trial proposals”
• “Results of a prospective randomised trial of adjuvant therapy for operable oesophageal cancer.”
Annual Scientific Congress, Royal Australasian College of Surgeons, Adelaide
• “Endoscopic oesophagectomy”
Seminars in Operative Surgery, Adelaide
• The role of surgery for high grade dysplasia in Barrett’s oesophagus
Australian Gastroenterology Week, Gastroenterology Society of Australia, Adelaide
• What should be the next trail for oesophageal cancer?
• Surgical results following resection for high grade dysplasia in Barrett’s
Australasian Gastro-intestinal Trials Group, Annual Scientific Meeting, Hobart.
• The management of oesophageal cancer
Caboolture Hospital Grand Rounds, Caboolture, Queensland.
• Recent trends in oesophageal cancer
Cairns Gut Club, Cairns, Queensland
• Update on neoadjuvant therapy for oesophageal cancer. The next trial?
International Society for Diseases of the Oesophagus, Australian Chapter, Lorne Victoria
• The role of multidisciplinary care for oesophageal carcinoma.
Clinical Oncology Society of Australia, Annual Scientific Meeting, Sydney, Australia.
2001: Invited Presentations
• “Update on the Surgery for Melanoma”
Gold Coast Oncology collaborative Group
• “Oesophageal Cancer – The next collaborative trial”
Annual Scientific Congress, Clinical Oncological Society of Australia, Brisbane.
• “Diagnosis and Management of Malignant Melanoma”
44th Annual Meeting RACGP (Qld Faculty), Gold Coast, Australia
• “Oesophageal Cancer – Adjuvant Therapy”
Annual Scientific Congress, Royal Australasian College of Surgeons, Canberra,
• “Management of Cutaneous Melanoma”
Mater Hospital Collaborative Oncology Group, Brisbane
• “Management of Pancreatic Injury”
Military and Civilian Trauma, Brisbane, Australia.
• “Management of Cutaneous Melanoma”
Redcliffe Hospital Clinical Meeting
• “The present status of adjuvant therapy for Oesophageal Cancer”
Australasian Gastrointestinal Trials Group, Annual Scientific Congress,
Sunshine Coast, Queensland.
•
•
•
“The role of a multidisciplinary clinic in the management of upper GI malignancy”
“Surgery for bulky groin secondaries of melanoma”
“A surgeons perspective of the role of adjuvant therapy for Melanoma”
Centenary Surgical Oncology Meeting, Brisbane, Australia
• “Long term results of Laparoscopic Fundoplication – The test of time”
Asia Pacific Gastroenterology Congress, Sydney, Australia.
2000: Refereed Presentations
• “Radiation Therapy – The forgotten tool in the fight against Melanoma”
Burmeister B, Smithers BM
• “Where to now with adjuvant therapy in oesophageal cancer?”
Smithers BM, Burmeister B
Annual Scientific Meeting, Clinical Oncological Society of Australia,
Adelaide, Australia
• “Phase II study assessing the role of radiotherapy after nodal surgery for metastatic
melanoma.”
Smithers BM, Burmeister B, Baumann K
Annual Scientific Congress, Royal Australiasian College of Surgeons,
Melbourne, Australia
• “Elective laparoscopic fundoplication for reflux: 1000 cases with 1-5 year follow-up”
Gotley DC, Smithers BM, Martin I, Bessell J, Doyle L, Menzies B, Nathanson L.
• “ Endoscopic versus open surgery for oesophageal cancer.”
Gotley DC, Smithers BM, Martin I, Bessell J, Doyle L.
7th World Congress of Endoscopic Surgery, 8th International Scientific Meeting of the
Endoscopic and Laparoscopic Surgeons of Asia. Singapore
Invited Presentations
• “Adjuvant therapy for Malignant Melanoma”
Head and Neck 2000 – Annual Meeting of the Australian and New Zealand Head
And Neck Society, Gold Coast, Queensland.
• “The new surgical training”
• “Endoscopic surgery and the oesophagus – techniques and results”
• “Update on the management of Melanoma”
Keynote Speaker, Northern Australian Surgeon’s Club – Annual Scientific Meeting
Port Douglas, Queensland
• “Barrett’s oesophagus natural history and surveillance.”
Gotley DC, Smithers BM, Martin I, Sanders G, Doyle LM
• “Laparoscopic versus open surgery for oesophageal cancer.”
Gotley DC, Smithers BM, Martin I, Bessell J, Doyle LM.
• “Oesophageal cancer: Neoadjuvant therapy.”
Smithers BM, Gotley DC, Doyle LM.
Annual Scientific Congress, Royal Australiasian College of Surgeons,
Melbourne, Australia
• Panel Participation: Case Symposium- “Management of Oesophageal Cancer”
GE Society of Queensland, 4th Annual Coolum Update in Gastroenterology and
Hepatology, Sunshine Coast, Queensland, Australia.
Posters
# Comparison of quality of life after laparoscopic fundoplication: Do Barrett’s patients fare
worse
DC Gotley, BM Smithers, LE Nathanson, I Martin, L Rutherford, L Doyle, B Menzies
# The natural history of high grade dysplasia in Barrett’s oesophagus.
BM Smithers, DC Gotley, G Sanders, LM Doyle
# Outcomes after minimally invasive surgery for high grade dysplasia in Barrett’s
oesophagus: short term follow up of Quality of life.
LM Doyle, BM Smithers, DC Gotley, L Rutherford, C Swanson
Organisation international d’Etudes Statistiques pour maladies de Oesophage (OESO)
World 6th Congress, Paris, France
Invited as Chairman
Session: Novel Therapies for Breast Cancer
Annual Scientific Meeting, Clinical Oncological Society of Australia, Adelaide
1999: Refereed Presentations
• “Elective laparoscopic fundoplication for reflux: 1000 consecutive cases with 1-5 year
follow-up”
DC Gotley, BM Smithers, I Martin, J Bessell, L Doyle, B Menzies, L Nathanson
• “High Grade Dysplasia in Barrett’s Oesophagus”
G Sanders, BM Smithers, DC Gotley, A Clouston
Australian Gastroenterology Week, Brisbane, Australia
• “Dysphagia after laparoscopic fundoplication”
JR Bessell, R Finch, DC Gotley, L Nathanson, BM Smithers, I Martin, L Doyle,
B Menzies
Annual Scientific Meeting, Surgical Research Society of Australasia,
Cairns, Australia
• “Palliative Chemo-radiotherapy (CRT) in Advanced Oesophageal Cancer”
J Harvey, B Burmeister, D Thomson, E Walpole, BM Smithers, D Gotley,
J Bessell, L Doyle
Annual Scientific Meeting, Clinical Oncological Society of Australia,
Melbourne, Australia
Invited Presentations
# “The Role of Chemoradiation in Oesophageal Cancer”
Asian Surgical Association, Brisbane, Australia
• “Chemoradiation and surgery for Oesophageal Carcinoma”
Guest Presentation, GI subcommittee, Victorian Clinical Oncology Group
Melbourne, Australia
• “Intergroup Oesophageal Study of Preoperative Chemoradiation for Operable
Oeophageal cancer”
Royal North Shore Hospital, Weekly Gastroenterology Meeting, Sydney, Australia
• “Preoperative Chemoradiation for Operable Oesophageal Carcinoma”
Royal Melbourne Hospital, Melbourne, Australia
# “Multicentre or Single Centre Clinical Trials?”
Surgical Forum, International Clinical Trials Symposium, Sydney, Australia
• “The Management of Pancreatic Trauma”
General Surgeons Australia, Scientific Meeting, Gold Coast, Australia
• “The Intergroup Oesophageal Cancer Trial”
“Trends in the Management of Malignant Melanoma”
Rural Surgeons Meeting, Victorian State Committee, Geelong, Victoria
Posters
• “The role of chemo-radiotherapy prescribed by a multidisciplinary team for the palliative
treatment of malignant dysphagia”. J Bessell, BM Smithers, DC Gotley, J Harvey,
BH Burmeister, I Martin, E Walpole, D Thomson
Australian Gastroenterology Week, Brisbane, Australia
Invited as Chairman
• “Video Forum”
Endoscopy Workshop, Australian Gastroenterology Week, Brisbane,
Australia
• “Gastric Cancer Surgery in 1999”
Annual Scientific Meeting, Clinical Oncological Society Of Australia,
Melbourne, Australia
1998: INTERNATIONAL INVITATION
• ATLS Courses x 2
Overseas Faculty Member, Queen Mary’s Hospital, Hong Kong
Invited Presentations
•

•
•
•
•
•
•
"Gastro-oesophageal reflux disease”
Rural Surgical Training Program – Trainees Meeting,Kingaroy, Queensland
# “Thoracoscopic Mobilisation of the Oesophagus”
Millenium Surgical Meeting, Gold Coast, Queensland
“The role of Chemoradiation in Oesophageal Cancer”
“Thoracoscopic Mobilisation of the Oesophagus”
Western Australian Clinical Oncology Group, Perth, West Australia
“Curative Therapy for Oesophageal Cancer- The role of surgery, chemotherapy and radiotherapy”
“Establishment of the Oesophageal Intergroup Trial”
Endoscopy and Research Workshops , Austrailian Gastroenterology Week
Canberra, Australia
“Current Concepts in Resusitation and Penetrating Trauma”
Annual Scientific meeting, Australian and New Zealand Society
of Anaesthetists, Queensland branch. Gold Coast, Queensland.
“Current status of the Oesophageal Cancer Trial IG9401”
Scientific Meeting, Australasian Gastro-Intestinal Trials Group, Sydney
Posters
• “Microdialysis probe development and optimal conditions for melphalan determination in
various tissues”
T Dorizzi, ZY Wu, R Haslam, BM Smithers, J. Thompson, C Anderson, MS Roberts
• “Melphalan tissue concentration in isolated limb perfusion by using the technique of
microdialysis”
ZY Wu, R Haslam, T Dorizzi, BM Smithers, J Thompson, C Anderson, MS Roberts
Australian Society of Clinical and Experimental Pharmacologists and
Toxicologists, Sydney, Australia
• “Previous radiation for breast cancer – an unusual cause of carcinoma of the oesophagus.
B Matheson, BH Burmeister, BM Smithers, D Gotley, JA Harvey, L Doyle.
• “Retrospective analysis of concurrent radiation and 5-Flurouracil (5FU) alone for
oesophageal cancer”. HG Juffs, DB Thomson, ET Walpole, JF MacKintosh,
BH Burmeister, JA Harvey, BM Smithers, DC Gotley
Annual Scientific Meeting of the Clinical Oncological Society of Australia,
Sydney, Australia
Invited as Chairman
• “Management of Gastro-oesophageal junction cancer”
Annual Scientific Meeting of The Clinical Oncological Society of Australia
Sydney, Australia
1997: Refereed Presentations
• “Thoracoscopic oesophageal mobilization for carcinoma”.
BM Smithers, DC Gotley, C Smith.
• “Successful application of laparoscopy to correction of gastro-oesophageal reflux”.
DC Gotley, BM Smithers, B Menzies, L Nathanson.
• “Establishing selective lyphadenectomy for cutaneous melanoma”.
BM Smithers, GRC McLeod, J Anderson, G Strutton.
Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane
•
“Radiation Therapy following nodal dissection for malignant melanoma: a report on a
phase II study”. BH Burmeister, MG Poulsen, BM Smithers, GR McLeod, JA Harvey,
K Morton.
4thWorld Conference on Melanoma, Sydney, Australia
Invited Presentations
• "What operation should be performed for carcinoma of the gastro-oesophageal junction"
Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, Australia.
• "What not to do in management of malignant melanoma"
4th World Conference on Melanoma, Sydney, Australia.
• "Future directions of General Surgery in Queensland"
Royal Australasian College of Surgery, Queensland Division Annual Scientific Meeting, Yeppoon,
Queensland, Australia
•
•
•
•
"Oesophageal Cancer" – Breakfast session.
Australian Gastroenterology Week, Brisbane, Australia
"Thoracoscopic Oesophageal Mobilization" – Video presentation.
"Diagnosis and Treatment of Early Upper Gastrointestinal Cancer – Australian View "
III Annual Gold Coast Surgical Weekend Conference
"Current Management of Oesophageal Cancer"
Surgical Meeting, Liverpool Hospital, Sydney, Australia
Posters
• "Metastatic malignant melanoma to the orbit: a report of nine cases".
JA Harvey, BH Burmeister, BM Smithers, GRC McLeod.
• "The trials and tribulations of establishing selective lymphadenectomy for cutaneous melanoma".
BM Smithers, GRC McLeod, J Anderson, G Strutton
• "The use of an animal model to explore conditions for isolated limb perfusion".
BM Smithers, ZY WU, PG Parsons, MS Roberts.
• "Melphalan dosing-regimens for the management of recurrent melanoma by isolated limb perfusion:
application of a physiological pharmacokinetic model based on melphalan distribution in the isolated
perfused rat hind limb".
ZY Wu, BM Smithers, MS Roberts.
4th World Conference on Melanoma, Sydney, Australia
Invited as Chairman
• "Management of Local Recurrence of Malignant Melanoma".
Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, Australia.
Jan 2011